Business Context and Reporting Period
Company: Tempest Therapeutics, Inc. (TPST)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Business Overview: Tempest is a clinical-stage biotechnology company focused on developing targeted and immune-mediated oncology therapies. Its lead program, amezalpat (TPST-1120), is a PPARα antagonist advancing toward a pivotal Phase 3 trial for first-line hepatocellular carcinoma (HCC). A second candidate, TPST-1495, is a dual EP2/EP4 antagonist being developed for Familial Adenomatous Polyposis (FAP) and endometrial cancer. The company has no approved products and has not generated product revenue.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(17,474) | $(15,217) |
| Net Loss Per Share (Basic & Diluted) | $(0.78) | $(1.09) |
| Cash and Cash Equivalents (End of Period) | $31,124 | $17,972 |
| Cash Used in Operating Activities | $(12,696) | $(14,695) |
| Total Debt (Loan Payable, net) | $10,653 | $10,549 |
| Accumulated Deficit | $(182,737) | $(150,989) |
Note: Total Debt includes $8,645 in current portion and $2,008 in non-current portion as of June 30, 2024.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by approximately 17% year-over-year for the six-month period, driven primarily by a 12% increase in Research and Development (R&D) expenses to $10.2 million. This increase was attributed to costs associated with preparing for the pivotal Phase 3 trial of amezalpat and increased stock-based compensation.
- Stock-Based Compensation: Stock-based compensation expense surged to $2.6 million for the six months ended June 30, 2024, compared to $0.9 million in the prior year period, reflecting increased headcount and equity grants.
- Liquidity Position: Cash balances increased significantly from $17.9 million in June 2023 to $31.1 million in June 2024. This improvement was supported by net proceeds of approximately $5.0 million from financing activities, primarily through an At-The-Market (ATM) offering program.
- Debt Structure: The company entered a new interest-only repayment period extension through June 30, 2024, with monthly principal payments of $733,000 commencing July 1, 2024.
Guidance, Outlook, and Risks
- Clinical Outlook: Management announced positive updated data for amezalpat in HCC, showing a median overall survival of 21 months versus 15 months for the control arm. The company anticipates receiving FDA feedback on a pivotal Phase 3 trial design in Q3 2024. TPST-1495 is expected to begin a Phase 2 study in FAP in the second half of 2024.
- Liquidity and Capital Needs: Management believes existing cash ($31.1 million) plus recent ATM proceeds ($1.4 million raised in July 2024) will fund operations for at least 12 months. However, the company expects to incur significant losses in the foreseeable future and will require additional capital to advance clinical trials and commercialization.
- Financing Activities: On June 20, 2024, the company terminated its prior ATM program and entered a new agreement allowing for the sale of up to $205 million of common stock. As of June 30, 2024, approximately $200.2 million remained available.
- Key Risks:
- Going Concern: The company has a history of operating losses and an accumulated deficit of $182.7 million. Continued operations depend on securing additional financing.
- Debt Covenants: The Oxford Finance loan agreement includes financial covenants and a lien on all assets, including intellectual property. Failure to comply could result in acceleration of debt.
- Regulatory Uncertainty: Success depends on obtaining regulatory approval for product candidates, which is uncertain and costly.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $31.1 million cash balance against projected burn rates for the upcoming pivotal Phase 3 trial of amezalpat.
- Debt Obligations: Confirm the impact of the new monthly principal payments ($733k) starting July 2024 on liquidity and covenant compliance with Oxford Finance.
- ATM Utilization: Monitor the pace of share issuance under the new $205 million ATM program and its potential dilutive effect on existing shareholders.
- Clinical Milestones: Track the timing and outcome of the anticipated FDA feedback in Q3 2024 regarding the Phase 3 trial design for amezalpat.
- Expense Trends: Assess the sustainability of the sharp increase in stock-based compensation and R&D costs relative to the company's cash position.